Edwards Lifesciences Financials

EW Stock  USD 71.27  0.79  1.12%   
Based on the key indicators related to Edwards Lifesciences' liquidity, profitability, solvency, and operating efficiency, Edwards Lifesciences Corp may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter. At this time, Edwards Lifesciences' Net Receivables is fairly stable compared to the past year. Liabilities And Stockholders Equity is likely to climb to about 9.8 B in 2024, whereas Common Stock Shares Outstanding is likely to drop slightly above 550.8 M in 2024. Key indicators impacting Edwards Lifesciences' financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Net Profit Margin0.250.2335
Notably Up
Slightly volatile
Return On Assets0.0780.1498
Way Down
Pretty Stable
Return On Equity0.110.2109
Way Down
Very volatile
Debt Equity Ratio0.08880.0935
Notably Down
Slightly volatile
Operating Income1.6 B1.5 B
Sufficiently Up
Slightly volatile
Current Ratio2.333.376
Way Down
Slightly volatile
Investors should never underestimate Edwards Lifesciences' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Edwards Lifesciences' cash flow, debt, and profitability to make informed and accurate decisions about investing in Edwards Lifesciences Corp.

Cash And Equivalents

1.01 Billion

  
Understanding current and past Edwards Lifesciences Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Edwards Lifesciences' financial statements are interrelated, with each one affecting the others. For example, an increase in Edwards Lifesciences' assets may result in an increase in income on the income statement.

Edwards Lifesciences Earnings Geography

Please note, the imprecision that can be found in Edwards Lifesciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Edwards Lifesciences Corp. Check Edwards Lifesciences' Beneish M Score to see the likelihood of Edwards Lifesciences' management manipulating its earnings.

Edwards Lifesciences Stock Summary

Edwards Lifesciences competes with Medtronic PLC, Abbott Laboratories, Boston Scientific, Zimmer Biomet, and Stryker. Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California. Edwards Lifesciences operates under Medical Devices classification in the United States and is traded on New York Stock Exchange. It employs 15700 people.
Foreign Associate
  Mexico
Specialization
Health Care, Health Care Equipment & Services
InstrumentUSA Stock View All
ExchangeNew York Stock Exchange
ISINUS28176E1082
CUSIP28176E108
LocationCalifornia; U.S.A
Business AddressOne Edwards Way,
SectorHealth Care Equipment & Supplies
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.edwards.com
Phone949 250 2500
CurrencyUSD - US Dollar

Edwards Lifesciences Key Financial Ratios

Edwards Lifesciences Key Balance Sheet Accounts

201920202021202220232024 (projected)
Total Assets6.5B7.2B8.5B8.3B9.4B9.8B
Other Current Liab6.4M574.7M677.3M673.3M821.9M863.0M
Retained Earnings3.7B4.6B6.1B7.6B9.0B9.4B
Net Receivables599.1M602.8M664.9M699.1M836.9M878.7M
Good Will1.2B1.2B1.2B1.2B1.3B688.6M
Inventory640.9M802.3M726.7M875.5M1.2B1.2B
Other Current Assets168M283.3M322.3M305.9M386.1M405.4M
Total Liab2.3B2.7B2.7B2.5B2.6B1.4B
Total Current Assets3.0B3.1B3.2B3.1B4.0B4.2B
Other Liab784.1M1.1B969.6M797.6M917.2M963.1M
Net Debt(500.3M)(488.3M)(172.5M)(77.7M)(449.1M)(426.6M)
Accounts Payable180.4M196.5M204.5M201.9M201.4M139.5M
Cash1.2B1.2B862.8M769M1.1B1.2B
Other Assets274M1.2B357.5M783.1M900.6M945.6M
Long Term Debt594.4M595M595.7M596.3M597M425.6M
Short Term Debt0.025.5M54.4M51M49.8M47.3M
Intangible Assets336.5M331.4M323.6M285.2M428.4M449.8M
Common Stock218.1M636.4M642M646.3M650.5M683.0M
Treasury Stock(1.0B)(1.3B)(1.9B)(2.4B)(2.2B)(2.1B)
Net Tangible Assets2.9B3.4B4.3B4.4B5.0B5.3B
Capital Surpluse1.6B1.4B1.7B2.0B2.3B1.2B

Edwards Lifesciences Key Income Statement Accounts

The reason investors look at the income statement is to determine what Edwards Lifesciences' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
201920202021202220232024 (projected)
Interest Expense20.7M15.8M18.4M19.2M17.6M10.6M
Total Revenue4.3B4.4B5.2B5.4B6.0B6.3B
Gross Profit3.2B3.3B4.0B4.3B4.6B4.9B
Operating Income1.1B1.6B1.3B1.7B1.5B1.6B
Ebit1.1B938.9M1.7B1.8B1.5B1.6B
Research Development752.7M760.7M903.1M945.2M1.1B1.1B
Ebitda1.3B1.1B1.9B2.0B1.5B1.6B
Cost Of Revenue1.1B1.1B1.2B1.1B1.4B697.9M
Income Before Tax1.2B916.7M1.7B1.8B1.6B1.7B
Net Income1.0B823.4M1.5B1.5B1.4B1.5B
Income Tax Expense119.6M93.3M198.9M245.5M198.7M113.1M
Non Recurring98M405.4M20.6M76.5M88.0M92.4M
Tax Provision119.6M93.3M198.9M245.5M207.6M201.8M
Net Interest Income11.5M7.6M(1M)16.3M40.7M42.7M
Interest Income32.2M7.6M1M16.3M67.2M70.6M

Edwards Lifesciences Key Cash Accounts

201920202021202220232024 (projected)
Change To Inventory(105.4M)(120.6M)19M(213.4M)(289M)(274.6M)
Free Cash Flow901M647M1.4B953.4M629.5M444.3M
Depreciation89.3M107.2M134.8M139.6M144.9M81.8M
Other Non Cash Items154.1M38.3M(119M)105.8M10.5M10.0M
Capital Expenditures278.4M407.3M329.8M264.8M266.3M146.6M
Net Income1.0B823.4M1.5B1.5B1.4B1.5B
Change In Cash465M15.8M(332.8M)(94.8M)375.4M394.2M
End Period Cash Flow1.2B1.2B867.4M772.6M1.1B1.2B
Dividends Paid18.9M140.5M158.6M146.4M169.9M233.1M
Investments(158.2M)(101.7M)(1.3B)252.3M254.4M267.1M
Change Receivables(88M)41.9M(91.1M)(84.1M)(75.7M)(71.9M)
Net Borrowings(10M)(800K)(1.8M)(200K)(180K)(171K)
Change To Netincome198.2M53.3M(79.6M)(49.1M)(56.5M)(53.6M)

Edwards Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Edwards Lifesciences's current stock value. Our valuation model uses many indicators to compare Edwards Lifesciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Edwards Lifesciences competition to find correlations between indicators driving Edwards Lifesciences's intrinsic value. More Info.
Edwards Lifesciences Corp is rated # 3 in return on equity category among its peers. It is one of the top stocks in return on asset category among its peers reporting about  0.56  of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Edwards Lifesciences Corp is roughly  1.80 . At this time, Edwards Lifesciences' Return On Equity is fairly stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Edwards Lifesciences by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Edwards Lifesciences Corp Systematic Risk

Edwards Lifesciences' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Edwards Lifesciences volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twelve with a total number of output elements of fourty-nine. The Beta measures systematic risk based on how returns on Edwards Lifesciences Corp correlated with the market. If Beta is less than 0 Edwards Lifesciences generally moves in the opposite direction as compared to the market. If Edwards Lifesciences Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Edwards Lifesciences Corp is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Edwards Lifesciences is generally in the same direction as the market. If Beta > 1 Edwards Lifesciences moves generally in the same direction as, but more than the movement of the benchmark.

Edwards Lifesciences Thematic Clasifications

Edwards Lifesciences Corp is part of several thematic ideas from Medical Equipment to Macroaxis Picks. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Get More Thematic Ideas
Today, most investors in Edwards Lifesciences Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Edwards Lifesciences' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Edwards Lifesciences growth as a starting point in their analysis.

Price Earnings To Growth Ratio

(5.14)

At this time, Edwards Lifesciences' Price Earnings To Growth Ratio is fairly stable compared to the past year.

Edwards Lifesciences November 26, 2024 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Edwards Lifesciences help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Edwards Lifesciences Corp. We use our internally-developed statistical techniques to arrive at the intrinsic value of Edwards Lifesciences Corp based on widely used predictive technical indicators. In general, we focus on analyzing Edwards Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Edwards Lifesciences's daily price indicators and compare them against related drivers.

Additional Tools for Edwards Stock Analysis

When running Edwards Lifesciences' price analysis, check to measure Edwards Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edwards Lifesciences is operating at the current time. Most of Edwards Lifesciences' value examination focuses on studying past and present price action to predict the probability of Edwards Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edwards Lifesciences' price. Additionally, you may evaluate how the addition of Edwards Lifesciences to your portfolios can decrease your overall portfolio volatility.